<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00764582</url>
  </required_header>
  <id_info>
    <org_study_id>VPH0109</org_study_id>
    <nct_id>NCT00764582</nct_id>
  </id_info>
  <brief_title>Ocular Penetration of 1.5% Levofloxacin and 0.5% Moxifloxacin During Corneal Transplant Surgery</brief_title>
  <official_title>A Randomized, Observer-masked, Parallel-group, Multicenter Trial Evaluating the Ocular Penetration of 1.5% Levofloxacin Ophthalmic Solution and 0.5% Moxifloxacin Ophthalmic Solution in Subjects Undergoing Corneal Transplant Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Santen Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vistakon Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Santen Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compare the corneal penetration of levofloxacin 1.5% and moxifloxacin 0.5% in patients
      undergoing penetrating keratoplasty (PK)
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study terminated due to lack of enrollment.
  </why_stopped>
  <start_date>September 2008</start_date>
  <primary_completion_date type="Anticipated">March 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration of levofloxacin and moxifloxacin in the corneal tissue</measure>
    <time_frame>Time of surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>4 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Corneal Transplantation</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1.5% levofloxacin ophthalmic solution</intervention_name>
    <description>Topical application Instill 1 drop two times, 5 minutes apart. Time from last drop to surgery is determined by group.
Group 1: 30 minutes prior to surgery
Group 2: 1 hour prior to surgery
Group 3: 2 hours prior to surgery
Group 4: 4 hours prior to surgery</description>
    <arm_group_label>1</arm_group_label>
    <other_name>IQUIX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.5% moxifloxacin ophthalmic solution</intervention_name>
    <description>Topical application Instill 1 drop two times, 5 minutes apart. Time from last drop to surgery is determined by group.
Group 5: 30 minutes prior to surgery
Group 6: 1 hour prior to surgery
Group 7: 2 hours prior to surgery
Group 8: 4 hours prior to surgery</description>
    <arm_group_label>2</arm_group_label>
    <other_name>VIGAMOX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Man or woman 18 years of age or older

          -  Scheduled for corneal transplant surgery

          -  Patients must be healthy enough to undergo surgery

          -  Women must be postmenopausal for at least 1 year or surgically sterile incapable of
             pregnancy

          -  Women must be abstinent at the discretion of the investigator

          -  Women practicing an effective method of birth control

          -  Women agree before entry to continue to use the same method of contraception
             throughout the study

          -  Women of childbearing potential must have a negative urine pregnancy test at screening

        Exclusion Criteria

          -  Presence of an active ocular infection or positive history of ocular herpetic
             infection

          -  History of severe dry eye syndrome

          -  Use of contact lenses in the 2 weeks prior to the study and for the duration of the
             study

          -  Received an experimental drug or used an experimental medical device within 30 days
             before the planned start of treatment

          -  Pregnant or breast feeding

          -  Employees of the investigator or study center with direct involvement in the proposed
             study or other studies under the direction of that investigator or study center as
             well as family members of the employees or the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Great Rapids</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 26, 2008</study_first_submitted>
  <study_first_submitted_qc>October 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2008</study_first_posted>
  <last_update_submitted>August 24, 2009</last_update_submitted>
  <last_update_submitted_qc>August 24, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2009</last_update_posted>
  <responsible_party>
    <name_title>Brian Schwam, MD</name_title>
    <organization>VISTAKON Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Corneal penetration of levofloxacin and moxifloxacin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eye Injuries, Penetrating</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

